0001213900-26-088347 | 10-Q | XBRL Viewer

Cover - shares	6 Months Ended
Cover - shares	Jun. 30, 2026	Aug. 07, 2026
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Entity Interactive Data Current	Yes
Amendment Flag	false
Document Period End Date	Jun. 30, 2026
Document Fiscal Year Focus	2026
Document Fiscal Period Focus	Q2
Entity Registrant Name	Bluejay Diagnostics, Inc.
Entity Central Index Key	0001704287
Entity File Number	001-41031
Entity Tax Identification Number	47-3552922
Entity Incorporation, State or Country Code	DE
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Address, Address Line One	360 Massachusetts Avenue
Entity Address, Address Line Two	Suite 203
Entity Address, City or Town	Acton
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01720
City Area Code	(844)
Local Phone Number	327-7078
Title of 12(b) Security	Common Stock
Trading Symbol	BJDX
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding		4,468,051

Subsequent Events (Details) - Pre-Funded Warrants [Member] - shares	6 Months Ended
	Jun. 30, 2026	Jul. 31, 2026
Subsequent Events [Line Items]
Unexercised Warrants	222,581
Subsequent Event [Member]
Subsequent Events [Line Items]
Excess Stock, Shares Issued		2,484,367

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - $ / shares	Jun. 30, 2026	Dec. 31, 2025
Statement of Financial Position [Abstract]
Common stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in Shares)	250,000,000	250,000,000
Common stock, shares issued (in Shares)	1,983,684	604,534
Common stock, outstanding (in Shares)	1,983,684	604,534

- Definition

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.6-05(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(16)(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(7))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

+ Details

Nature of Operations and Basis of Presentation (Details) - USD ($)			3 Months Ended	6 Months Ended
	Jun. 09, 2026	Jan. 29, 2026	Jun. 30, 2024	Jun. 30, 2026	Dec. 31, 2027	Dec. 31, 2025
Nature of Operations and Basis of Presentation [Line Items]
Cash and cash equivalents				$ 9,598,916		$ 5,164,875
Current liabilities				2,116,641		1,119,197
Accumulated deficit				$ (45,760,521)		$ (41,517,267)
Incorporated date				Mar. 20, 2015
Patient mortality period			28 days
Cumulative risk period				28 days
Reverse stock split period				12 months
Bid price				$ 1
Minimum [Member] \| Forecast [Member]
Nature of Operations and Basis of Presentation [Line Items]
Expected raise of capital					$ 10,000,000
Maximum [Member] \| Forecast [Member]
Nature of Operations and Basis of Presentation [Line Items]
Expected raise of capital					$ 14,000,000
Common Stock [Member]
Nature of Operations and Basis of Presentation [Line Items]
Number of common stock (in Shares)	500,000
January 2026 Reverse Stock Split [Member] \| Common Stock [Member]
Nature of Operations and Basis of Presentation [Line Items]
Reverse stock split ratio		1-for-4
Additional Reverse Stock Split [Member] \| Common Stock [Member]
Nature of Operations and Basis of Presentation [Line Items]
Reverse stock split ratio	1-for-20

Significant Accounting Policies

6 Months Ended

Jun. 30, 2026

Significant Accounting Policies [Abstract]

SIGNIFICANT ACCOUNTING POLICIES

2. SIGNIFICANT ACCOUNTING POLICIES

During the six months ended June 30, 2026, there were no changes to the significant accounting policies as described in the 2025 Audited Financial Statements.

Use of Estimates

The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in these consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates. The Company evaluates its estimates and assumptions as facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ from these estimates and assumptions, and those differences could be material to the consolidated financial statements.

Warrants

The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in the Financial Accounting Standards Board, or the FASB, ASC 480, Distinguishing Liabilities from Equity, or ASC 480, and ASC 815 Derivatives and Hedging, or ASC 815. The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own stock and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. Finally, the Company determines if the warrants meet the definition of a derivative based on their contractual terms. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.

For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and at each balance sheet date thereafter. The Company uses the Black Scholes option pricing model to determine fair value. Changes in the estimated fair value of liability-classified warrants are recognized as a non-cash gain or loss on the consolidated statements of operations. The Company also evaluates if changes in contractual terms or other considerations would result in the reclassification of outstanding warrants from liabilities to stockholders’ equity (or vice versa).

Segment Reporting

The Company follows the guidance in ASC 280, Segment Reporting. Management has determined that the Company operates as one operating and reportable segment, as the Chief Executive Officer, who serves as the Chief Operating Decision Maker, evaluates performance of the operating segment and allocates resources based on amounts as reported on the consolidated statements of operations and cash flows. Segment expenses are presented on the Company’s consolidated statements of operations. The operating segment assets are reported on the consolidated balance sheets as total assets. The Company’s operations consist solely of the development of its Symphony diagnostic platform, a near-patient diagnostic platform designed to provide rapid results for critical care settings, and no discrete financial information is produced for separate business components. Accordingly, the consolidated financial statements represent the Company’s single reportable segment.

Net Loss per Share

Basic net loss per share to common stockholders is computed by dividing the net loss applicable to common stockholders by the weighted-average number of shares of common stock outstanding for the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock and dilutive common stock equivalents outstanding for the period determined using the treasury stock and if-converted methods. Dilutive common stock equivalents are comprised of options outstanding under the Company’s stock option plan, restricted stock units, and warrants. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities would be antidilutive.

Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows (in common stock equivalent shares):

	June 30,
Potentially Dilutive Securities Listing:	2026		2025
Options to purchase common stock		5		18
Warrants for common stock		152		165
Class A warrants for common stock		77		77
Class B warrants for common stock		2		2
January 2024 warrants for common stock		1,682		1,682
January 2024 placement agent warrants for common stock		117		117
Class C warrants for common stock		71,873		71,873
Class E warrants for common stock		271,277		271,277
Series F warrants for common stock		1,125,000		-
Series F placement agent warrants for common stock		45,000		-
Series G warrants for common stock		3,655,917		-
Series G placement agent warrants for common stock		255,914		-
Series H warrants for common stock		3,655,917		-

Recently Issued Accounting Standards

Expense Disaggregation Disclosures

In November 2024, the FASB issued ASU 2024-03, Reporting Comprehensive Income-Expense Disaggregation Disclosures. This change requires disaggregated disclosures of certain categories of expenses that are included in expense line items on the face of the income statement. The disclosures are required on an annual and interim basis. The guidance also requires the total amount of selling expenses to be disclosed and, on an annual basis, the definition of selling expenses. The guidance will be effective for annual reporting periods beginning after December 15, 2026, and for interim periods beginning after December 15, 2027. Early adoption is permitted. This new guidance will result in increased disclosures in the notes to the financial statements.

Financings

6 Months Ended

Jun. 30, 2026

Financings [Abstract]

FINANCINGS

4. FINANCINGS

June 2026 Private Placement

On June 2, 2026, the Company entered into a securities purchase agreement and registration rights agreement with certain institutional, accredited investors pursuant to which the Company sold in a private placement (i) pre-funded warrants to purchase up to 3,655,917 shares of common stock (the “June 2026 Pre-Funded Warrants”), (ii) Series G warrants (the “Series G Warrants”) to purchase up to 3,655,917 shares of common stock and (iii) Series H warrants (the “Series H Warrants”) to purchase up to 3,655,917 shares of common stock. The combined price of the securities sold in the private placement was $2.3249 per Pre-Funded Warrant and accompanying Series G Warrant and Series H Warrant. The June 2026 Pre-Funded Warrants are immediately exercisable for shares of common stock at an exercise price of $0.0001 per share, and expire once exercised in full. As of August 7, 2026, 3,433,336 of the June 2026 Pre-Funded Warrants have been exercised and 222,581 remain unexercised and outstanding. The Series G Warrants and Series H Warrants are immediately exercisable for shares of common stock at an exercise price of $2.075 per share. The Series G Warrants expire on June 26, 2031 and the Series H Warrants expire on June 26, 2028.

The transaction closed on June 5, 2026. The gross proceeds to the Company from the sale of the securities sold in the private placement were approximately $8.5 million. The Company incurred total offering costs of $942,262, including a 7% financial advisory fee to H.C. Wainwright & Co. (“Wainwright”), the placement agent, of approximately $595,000. Under the terms of the Company’s engagement letter with Wainwright, the Company issued Wainwright (or its designees) warrants to purchase up to 255,914 shares of common stock on the same terms as the Series G Warrants, except that the exercise price is $2.9063 per share (the “June 2026 Placement Agent Warrants”).

In connection with this private placement, the Company filed a registration statement on Form S-3, which became effective on June 26, 2026 to register 11,223,665 shares of common stock (including any shares of common stock issued in the future pursuant to the Series G Warrants, the Series H Warrants or June 2026 Placement Agent Warrants) for resale in public markets.

Holders of the warrants will not have the right to exercise any portion of such warrants if such holder, together with its affiliates, would beneficially own in excess of 4.99% or 9.99% (at the initial election of the holder) of the number of shares of the Company’s common stock outstanding immediately after giving effect to such exercise, provided that a holder may increase or decrease such beneficial ownership limitation up to, and no higher than, 9.99%, by giving 61 calendar days’ notice to the Company.

March 2026 Private Placement

On March 14, 2026, the Company entered into a securities purchase agreement pursuant to which the Company issued and sold to the purchasers named therein an aggregate of 62,500 shares of the Company’s common stock at a price of $2.00 per share. The transaction closed on March 17, 2026 for aggregate gross proceeds to the Company of $125,000.

The purchasers were Neil Dey, President and Chief Executive Officer of the Company and a director, Donald Chase, Chairman of the Board, and Svetlana Dey, Douglas Wurth and Fred Zeidman, each of whom are Company directors. Each of the purchasers acquired 12,500 shares of common stock for their own individual account. See Note 7 Related Party Transactions.

The sale was not registered under the Securities Act of 1933, as amended (the “Securities Act”), and the shares were issued and sold in a private placement pursuant to Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D as promulgated by the Securities and Exchange Commission under the Securities Act. Each of the purchasers represented that it is an “accredited investor” within the meaning of Rule 501 of Regulation D, was acquiring the shares for his or her own account, and had no direct or indirect arrangement or understanding with any other persons to distribute or regarding the distribution of such shares. The shares were offered and sold without any general solicitation by the Company or its representatives. The Company has not agreed to provide registration rights with respect to any of the shares.

On October 9, 2025, the Company entered into a securities purchase agreement with two institutional investors pursuant to which the Company sold in a private placement (i) an aggregate of 43,750 shares of common stock and prefunded warrants to purchase up to 518,750 shares of common stock (the “October 2025 Prefunded Warrants”), and (ii) Series F warrants (the “Series F Warrants”) to purchase up to 1,125,000 shares of common stock. The combined price of the securities sold in the private placement was $8.00 per share of common stock (or prefunded warrant in lieu thereof, in which case such price was reduced by $0.0004) and accompanying Series F Warrants to acquire two shares of common stock. The October 2025 Prefunded Warrants were exercisable for shares of common stock at an exercise price of $0.0004 per share, are immediately exercisable and expire once exercised in full. As of March 31, 2026, all of the October 2025 Prefunded Warrants were exercised in full. The Series F Warrants are exercisable for shares of common stock at an exercise price of $7.00 per share, are immediately exercisable and expire five and one-half years from the date of issuance.

The transaction closed on October 10, 2025. The gross proceeds to the Company from the sale of the securities sold in the private placement were approximately $4.5 million. The Company incurred total offering costs of $787,755, including a 8% financial advisory fee to Rodman and Renshaw LLC (“Rodman”), the placement agent, of approximately $360,000. Under the terms of the Company’s engagement letter with Rodman, the Company issued Rodman’s designees warrants to purchase up to 45,000 of common stock at an exercise price of $10.00 per share, which expire 5.5 years from the date of issuance (the “October 2025 Placement Agent Warrants”).

In connection with this private placement, the Company filed a registration statement on Form S-3, which became effective on November 26, 2025 to register 1,732,500 shares of common stock (including any shares of common stock issued in the future pursuant to the Series F Warrants or October 2025 Placement Agent Warrants) for resale in public markets.

April 2025 Private Placement

On April 7, 2025, the Company entered into inducement letter agreements with certain existing holders of the Company’s Class C warrants (the “Class C Warrants”), pursuant to which such holders agreed to purchase an aggregate of 271,277 shares of the Company’s common stock (or, to the extent the applicable holder would have exceeded a specified beneficial ownership limitation, prefunding the future exercise of such warrants, other than a remaining $0.0004 per share exercise price). The Class C Warrants were originally issued on June 28, 2024 for an exercise price of $392.00 per share and were subsequently reduced to $65.20 per share pursuant to stockholder approval on August 21, 2024. Pursuant to the inducement letter agreements, the applicable holders agreed to exercise their Series C Warrants at a reduced exercise price of $13.68 per share, and to purchase an equivalent number of new Class E warrants (the “Class E Warrants”) for an additional $0.50 per share. The Class E Warrants have an exercise price of $13.68 per share and expire on April 8, 2030.

The transaction closed on April 8, 2025. The exercise of the Class C Warrants resulted in the Company issuing 170,551 shares of common stock at closing pursuant to the inducement letters, and the exercise price of 100,726 of the Class C Warrants being amended to $0.0004 per share. As of December 31, 2025, all such reduced exercise price Class C Warrants had been exercised.

The gross proceeds to the Company from the exercise of the Class C Warrants and the sale of the new Class E Warrants were $3,846,692. The Company incurred total cash offering costs of $464,670, including a 10% financial advisory fee to Aegis Capital Corp. of $384,670.

The modification of the terms or conditions of the Class C Warrants in this transaction is treated as an exchange of the original instrument for a new instrument. Using the Black Scholes option pricing model, the fair value of the Series C Warrants immediately prior to the inducement transaction was $479,299 and immediately after the inducement transaction was $1,590,930. In addition, Series E Warrants with a fair value of $1,730,652 were provided as part of the inducement transaction for a purchase price of $135,638. The Company recorded additional equity issuance costs of $2,706,645 related to the modification of the Series C Warrants and issuance of Series E Warrants related to the inducement transaction. As this equity issuance cost was a non-cash transaction, the Company recorded an increase to additional paid-in capital to offset the expense.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480657/210-10-S50-8

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(19)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(a)(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(a)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(a)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(19))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480657/210-10-S50-9

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 470
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/470/tableOfContent

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

+ Details

Leases - Schedule of Estimated Operating Lease Payments (Details)

Jun. 30, 2026

USD ($)

Schedule of Estimated Operating Lease Payments [Abstract]

2026

$ 50,000

^[1]

2027

25,000

Thereafter

Total future lease payments

75,000

Less: Imputed interest

1,556

Present value of lease liability

$ 73,444

[1]	Excludes the six months ended June 30, 2026

Property and Equipment

6 Months Ended

Jun. 30, 2026

Property and Equipment [Abstract]

PROPERTY AND EQUIPMENT

8. PROPERTY AND EQUIPMENT

Property and equipment consisted of the following at June 30, 2026 and December 31, 2025:

	Depreciable lives	June 30, 2026			December 31, 2025
Construction-in-process		$	1,428,197		$	1,279,173
Manufacturing equipment	3-5 years		239,872			239,872
Furniture, Fixtures and equipment	3-5 years		132,671			116,782
Leasehold improvements	Shorter of useful life or life of lease		43,231			43,231
			1,843,971			1,679,058
Less: accumulated depreciation			(200,574	)		(144,617	)
Property and equipment, net		$	1,643,397		$	1,534,441

The Company reviews long-lived assets for impairment when events, expectations, or changes in circumstances indicate that the asset’s carrying value may not be recoverable. During the year ended December 31, 2025, the Company made the decision to close its internal lab and transferred the related fixed assets with a net book value of $62,376 to a third party to be marketed and sold. The Company wrote-off $9,549 of lab equipment and recognized an impairment charge of $26,706, both of which are included in research and development expenses. During the six months ended June 30, 2026, the Company returned assets held for sale of $3,150, which is recorded as Furniture, fixtures and equipment in the Company’s balance sheets, and wrote-off an additional $2,880 of assets held for sale.

Construction in process consists of symphony cartridge manufacturing equipment. The Company expects to place the remaining construction-in-process into service in 2026 to support its SYMON II clinical study. The Company has $1,105,440 of construction in process and $179,904 of manufacturing equipment held and operated by Sanyoseiko Co. LTD, its contract manufacturing organization in Japan.

- Definition

The entire disclosure for property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482099/360-10-50-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482099/360-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 360
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/360/tableOfContent

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482099/360-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482130/360-10-45-13

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.CC)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-SubTopic 360
-Topic 958
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477798/958-360-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-SubTopic 360
-Topic 958
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477798/958-360-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-SubTopic 360
-Topic 958
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477798/958-360-50-7

+ Details

Related Party Transactions - Schedule of Due from Related Parties (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Income from NanoHybrids included in other income [Member]
Schedule of Due from Related Parties [Line Items]
Balances due from related party				$ 6,873
Cash receipts from NanoHybrids [Member]
Schedule of Due from Related Parties [Line Items]
Balances due from related party		$ 6,873		$ 21,437

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

+ Details

Condensed Consolidated Statements of Changes in Stockholders’ Equity (Unaudited) - USD ($)	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Balance at Dec. 31, 2024	$ 14	$ 40,398,269	$ (34,668,784)	$ 5,729,499
Balance (in Shares) at Dec. 31, 2024	138,503
Statement [Line Items]
Stock-based compensation expense		1,312		1,312
Net loss			(1,864,435)	(1,864,435)
Balance at Mar. 31, 2025	$ 14	40,399,581	(36,533,219)	3,866,376
Balance (in Shares) at Mar. 31, 2025	138,503
Balance at Dec. 31, 2024	$ 14	40,398,269	(34,668,784)	5,729,499
Balance (in Shares) at Dec. 31, 2024	138,503
Statement [Line Items]
Net loss				(3,821,039)
Balance at Jun. 30, 2025	$ 37	43,780,017	(38,489,823)	5,290,231
Balance (in Shares) at Jun. 30, 2025	373,546
Balance at Mar. 31, 2025	$ 14	40,399,581	(36,533,219)	3,866,376
Balance (in Shares) at Mar. 31, 2025	138,503
Statement [Line Items]
Stock-based compensation expense		(1,563)		(1,563)
Issuance of common stock for vested restricted stock units
Issuance of common stock for vested restricted stock units (in Shares)	4
Issuance of common stock in connection with April 2025 Warrant Inducement, net of issuance costs of $464,670 and warrant inducement costs of $2,706,645	$ 23	675,354		675,377
Issuance of common stock in connection with April 2025 Warrant Inducement, net of issuance costs of $464,670 and warrant inducement costs of $2,706,645 (in Shares)	235,039
Warrant inducement cost		2,706,645		2,706,645
Net loss			(1,956,604)	(1,956,604)
Balance at Jun. 30, 2025	$ 37	43,780,017	(38,489,823)	5,290,231
Balance (in Shares) at Jun. 30, 2025	373,546
Balance at Dec. 31, 2025	$ 60	47,492,496	(41,517,267)	5,975,289
Balance (in Shares) at Dec. 31, 2025	604,534
Statement [Line Items]
Exercise of October 2025 Pre-Funded Warrants	$ 37	110		147
Exercise of October 2025 Pre-Funded Warrants (in Shares)	367,681
Issuance of common stock in connection with the March 2026 Private Placement	$ 6	124,994		125,000
Issuance of common stock in connection with the March 2026 Private Placement (in Shares)	62,500
Net loss			(1,919,241)	(1,919,241)
Balance at Mar. 31, 2026	$ 103	47,617,600	(43,436,508)	4,181,195
Balance (in Shares) at Mar. 31, 2026	1,034,715
Balance at Dec. 31, 2025	$ 60	47,492,496	(41,517,267)	5,975,289
Balance (in Shares) at Dec. 31, 2025	604,534
Statement [Line Items]
Net loss				(4,243,254)
Balance at Jun. 30, 2026	$ 198	55,175,163	(45,760,521)	9,414,840
Balance (in Shares) at Jun. 30, 2026	1,983,684
Balance at Mar. 31, 2026	$ 103	47,617,600	(43,436,508)	4,181,195
Balance (in Shares) at Mar. 31, 2026	1,034,715
Statement [Line Items]
Issuance of June 2026 Pre-Funded Warrants in connection with June 2026 Private Placement, net of issuance costs of $942,262		7,557,827		7,557,827
Exercise of June 2026 Pre-Funded Warrants	$ 95	(264)		(169)
Exercise of June 2026 Pre-Funded Warrants (in Shares)	948,969
Net loss			(2,324,013)	(2,324,013)
Balance at Jun. 30, 2026	$ 198	$ 55,175,163	$ (45,760,521)	$ 9,414,840
Balance (in Shares) at Jun. 30, 2026	1,983,684

Warrants - Schedule of Information with Regard to Warrants Outstanding (Details)	6 Months Ended
	Jun. 30, 2026 $ / shares shares
June 2026 Pre-funded warrants [Member]
Schedule of Information with Regard to Warrants Outstanding [Line Items]
Warrants outstanding, Shares \| shares	2,706,948
Warrants outstanding, Exercisable for	Common Stock
Warrants outstanding, Weighted Average Exercise Price \| $ / shares	$ 0.0001
Warrants outstanding, Weighted Average Remaining Life (in Years)
Series G warrants [Member]
Schedule of Information with Regard to Warrants Outstanding [Line Items]
Warrants outstanding, Shares \| shares	3,655,917
Warrants outstanding, Exercisable for	Common Stock
Warrants outstanding, Weighted Average Exercise Price \| $ / shares	$ 2.075
Warrants outstanding, Weighted Average Remaining Life (in Years)	5 years
June 2026 Placement Agent warrants [Member]
Schedule of Information with Regard to Warrants Outstanding [Line Items]
Warrants outstanding, Shares \| shares	255,914
Warrants outstanding, Exercisable for	Common Stock
Warrants outstanding, Weighted Average Exercise Price \| $ / shares	$ 2.906
Warrants outstanding, Weighted Average Remaining Life (in Years)	5 years
Series H warrants [Member]
Schedule of Information with Regard to Warrants Outstanding [Line Items]
Warrants outstanding, Shares \| shares	3,655,917
Warrants outstanding, Exercisable for	Common Stock
Warrants outstanding, Weighted Average Exercise Price \| $ / shares	$ 2.075
Warrants outstanding, Weighted Average Remaining Life (in Years)	2 years
Series F warrants [Member]
Schedule of Information with Regard to Warrants Outstanding [Line Items]
Warrants outstanding, Shares \| shares	1,125,000
Warrants outstanding, Exercisable for	Common Stock
Warrants outstanding, Weighted Average Exercise Price \| $ / shares	$ 7
Warrants outstanding, Weighted Average Remaining Life (in Years)	4 years 9 months 18 days
Series F Placement Agent warrants [Member]
Schedule of Information with Regard to Warrants Outstanding [Line Items]
Warrants outstanding, Shares \| shares	45,000
Warrants outstanding, Exercisable for	Common Stock
Warrants outstanding, Weighted Average Exercise Price \| $ / shares	$ 10
Warrants outstanding, Weighted Average Remaining Life (in Years)	4 years 9 months 18 days
Class E warrants [Member]
Schedule of Information with Regard to Warrants Outstanding [Line Items]
Warrants outstanding, Shares \| shares	271,277
Warrants outstanding, Exercisable for	Common Stock
Warrants outstanding, Weighted Average Exercise Price \| $ / shares	$ 13.68
Warrants outstanding, Weighted Average Remaining Life (in Years)	3 years 9 months 18 days
Class C warrants [Member]
Schedule of Information with Regard to Warrants Outstanding [Line Items]
Warrants outstanding, Shares \| shares	71,873
Warrants outstanding, Exercisable for	Common Stock
Warrants outstanding, Weighted Average Exercise Price \| $ / shares	$ 65.2
Warrants outstanding, Weighted Average Remaining Life (in Years)	3 years
January 2024 warrants [Member]
Schedule of Information with Regard to Warrants Outstanding [Line Items]
Warrants outstanding, Shares \| shares	1,682
Warrants outstanding, Exercisable for	Common Stock
Warrants outstanding, Weighted Average Exercise Price \| $ / shares	$ 2,080
Warrants outstanding, Weighted Average Remaining Life (in Years)	2 years 6 months
January 2024 Placement Agent warrants [Member]
Schedule of Information with Regard to Warrants Outstanding [Line Items]
Warrants outstanding, Shares \| shares	117
Warrants outstanding, Exercisable for	Common Stock
Warrants outstanding, Weighted Average Exercise Price \| $ / shares	$ 2,600
Warrants outstanding, Weighted Average Remaining Life (in Years)	2 years 6 months
August 2023 Common Stock warrants [Member]
Schedule of Information with Regard to Warrants Outstanding [Line Items]
Warrants outstanding, Shares \| shares	134
Warrants outstanding, Exercisable for	Common Stock
Warrants outstanding, Weighted Average Exercise Price \| $ / shares	$ 11,584
Warrants outstanding, Weighted Average Remaining Life (in Years)	2 years 2 months 12 days
August 2023 Placement Agent warrants [Member]
Schedule of Information with Regard to Warrants Outstanding [Line Items]
Warrants outstanding, Shares \| shares	8
Warrants outstanding, Exercisable for	Common Stock
Warrants outstanding, Weighted Average Exercise Price \| $ / shares	$ 14,736
Warrants outstanding, Weighted Average Remaining Life (in Years)	2 years 2 months 12 days
Class A warrants [Member]
Schedule of Information with Regard to Warrants Outstanding [Line Items]
Warrants outstanding, Shares \| shares	77
Warrants outstanding, Exercisable for	Common Stock
Warrants outstanding, Weighted Average Exercise Price \| $ / shares	$ 224,000
Warrants outstanding, Weighted Average Remaining Life (in Years)	3 months 18 days
Class B warrants [Member]
Schedule of Information with Regard to Warrants Outstanding [Line Items]
Warrants outstanding, Shares \| shares	2
Warrants outstanding, Exercisable for	Common Stock
Warrants outstanding, Weighted Average Exercise Price \| $ / shares	$ 320,000
Warrants outstanding, Weighted Average Remaining Life (in Years)	3 months 18 days
Common Stock [Member] \| Other Pre-2024 Common Stock Warrants [Member]
Schedule of Information with Regard to Warrants Outstanding [Line Items]
Warrants outstanding, Shares \| shares	10
Warrants outstanding, Exercisable for	Common Stock
Warrants outstanding, Weighted Average Exercise Price \| $ / shares	$ 148,000
Warrants outstanding, Weighted Average Remaining Life (in Years)	2 months 12 days

Stock Compensation (Tables)

6 Months Ended

Jun. 30, 2026

Stock Compensation [Abstract]

Schedule of Stock Option Activity

The following is a summary of stock option activity for the six months ended June 30, 2026:

	Number of Stock Options		Weighted Average Exercise Price Per Share		Weighted Average Remaining Contractual Life in Years		Aggregate Intrinsic Value
Outstanding at December 31, 2025		5	$	20,376		3.0	$	-
Granted		-		-		-		-
Exercised		-		-		-		-
Cancelled and forfeited		-		-		-		-
Outstanding at June 30, 2026		5	$	20,376		2.5	$	-
Exercisable at June 30, 2026		5	$	20,376		2.5	$	-

Schedule of Stock-Based Compensation Expense

Stock-Based Compensation Expense

For the three and six months ended June 30, 2026, and 2025, the Company recorded stock-based compensation expense as follows:

	Three Months Ended June 30,					Six Months Ended June 30,
	2026		2025			2026		2025
Research and development	$	-	$	(1,563	)	$	-	$	(450	)
General and administrative		-		-			-		199
Total stock-based compensation	$	-	$	(1,563	)	$	-	$	(251	)

Related Party Transactions (Details) - USD ($)				1 Months Ended	6 Months Ended
Related Party Transactions (Details) - USD ($)	Mar. 17, 2026	Mar. 14, 2026	May 08, 2025	Dec. 31, 2021	Jun. 30, 2026	Jun. 30, 2025
Related Party Transactions [Line Items]
Aggregate gross proceeds					$ 8,624,835	$ 3,846,692
Bill rate additional cost percentage				10.00%
NanoHybrids Inc. [Member]
Related Party Transactions [Line Items]
Payment to related party			$ 50,000
Payment for reimburse			$ 30,000
March 2026 Private Placement [Member]
Related Party Transactions [Line Items]
Purchase agreement (in Shares)		62,500			12,500
Aggregate gross proceeds	$ 125,000
Common Stock [Member] \| March 2026 Private Placement [Member]
Related Party Transactions [Line Items]
Common stock at a price (in Dollars per share)		$ 2

License and Supply Agreement with Toray Industries (Details) - New Toray License Agreement [Member] - USD ($)				3 Months Ended		6 Months Ended
	Oct. 23, 2025	Oct. 23, 2023	Oct. 06, 2020	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
License and Supply Agreement with Toray Industries [Line Items]
Payments to toray			$ 120,000
Minimum annual royalty payments			60,000
Royalty payments for each year			$ 100,000
Term of cartridges		10 years
Reduction in royalty rate		50.00%
Amount paid for final supply of chip component	$ 71,212
Sales or revenues from cartridges
Accrued amounts
Minimum [Member]
License and Supply Agreement with Toray Industries [Line Items]
Royalty payment percentage payable		15.00%
Maximum [Member]
License and Supply Agreement with Toray Industries [Line Items]
Royalty payment percentage payable		7.50%

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Jun. 30, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 9,598,916	$ 5,164,875
Prepaid expenses and other current assets	202,971	275,957
Assets held for sale	13,065	22,770
Total current assets	9,814,952	5,463,602
Property and equipment, net	1,643,397	1,534,441
Operating lease right-of-use assets	69,290	113,289
Other non-current assets	6,261	7,905
Total assets	11,533,900	7,119,237
Current liabilities:
Accounts payable	674,089	214,255
Operating lease liability, current	73,444	100,000
Accrued expenses and other current liabilities	1,369,108	804,942
Total current liabilities	2,116,641	1,119,197
Operating lease liability, non-current		20,211
Other non-current liabilities	2,419	4,540
Total liabilities	2,119,060	1,143,948
Commitments and Contingencies (See Note 10)
Stockholders’ equity:
Common stock, $0.0001 par value; 250,000,000 shares authorized; 1,983,684 and 604,534 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively	198	60
Additional paid-in capital	55,175,163	47,492,496
Accumulated deficit	(45,760,521)	(41,517,267)
Total stockholders’ equity	9,414,840	5,975,289
Total liabilities and stockholders’ equity	$ 11,533,900	$ 7,119,237

Supplemental Balance Sheet Information - Schedule of Supplemental Balance Sheet Information (Details) - USD ($)	Jun. 30, 2026	Dec. 31, 2025
Schedule of Supplemental Balance Sheet Information [Abstract]
Prepaid insurance	$ 83,337	$ 183,211
Prepaid and other	119,634	92,746
Total prepaid expenses and other current assets	202,971	275,957
Accrued personnel costs	91,911	47,117
Accrued legal fees	169,383	43,077
Accrued clinical trial expenses	822,178	274,532
Accrued board of director fees	147,500	147,500
Accrued other	138,136	156,567
Accrued Delaware franchise tax		136,149
Total accrued expenses and other current liabilities	$ 1,369,108	$ 804,942

Stock Compensation

6 Months Ended

Jun. 30, 2026

Stock Compensation [Abstract]

STOCK COMPENSATION

6. STOCK COMPENSATION

Stock Incentive Plans

In 2018, the Company adopted the 2018 Stock Incentive Plan (the “2018 Plan”) for employees, consultants, and directors. The 2018 Plan, which is administered by the Board of Directors, permits the Company to grant incentive and nonqualified stock options for the purchase of common stock, and restricted stock awards. The maximum number of shares reserved for issuance under the 2018 Plan is 20. At June 30, 2026, there were 9 shares available for grant under the 2018 Plan.

On July 6, 2021, the Company’s board of directors and stockholders approved and adopted the Bluejay Diagnostics, Inc. 2021 Stock Plan (the “2021 Stock Plan”). A total of 61 shares of common stock were approved to be initially reserved for issuance under the 2021 Stock Plan. On April 28, 2026, the Company’s board of directors approved Amendment No. 1 to the 2021 Stock Plan, which was further approved by the shareholders on June 9, 2026, to increase the number of shares of common stock issuable by 600,000. At June 30, 2026, there were 600,025 shares available for grant under the 2021 Plan.

Stock Award Activity

The following is a summary of stock option activity for the six months ended June 30, 2026:

	Number of Stock Options		Weighted Average Exercise Price Per Share		Weighted Average Remaining Contractual Life in Years		Aggregate Intrinsic Value
Outstanding at December 31, 2025		5	$	20,376		3.0	$	-
Granted		-		-		-		-
Exercised		-		-		-		-
Cancelled and forfeited		-		-		-		-
Outstanding at June 30, 2026		5	$	20,376		2.5	$	-
Exercisable at June 30, 2026		5	$	20,376		2.5	$	-

There were no stock options or restricted stock awards granted during the six months ended June 30, 2026.

Stock-Based Compensation Expense

For the three and six months ended June 30, 2026, and 2025, the Company recorded stock-based compensation expense as follows:

	Three Months Ended June 30,					Six Months Ended June 30,
	2026		2025			2026		2025
Research and development	$	-	$	(1,563	)	$	-	$	(450	)
General and administrative		-		-			-		199
Total stock-based compensation	$	-	$	(1,563	)	$	-	$	(251	)

At June 30, 2026, there was no unrecognized compensation expense related to non-vested stock option awards and non-vested restricted stock awards.

Significant Accounting Policies - Schedule of Potentially Dilutive Securities of Diluted Net Loss Per Share (Details) - shares	Jun. 30, 2026	Jun. 30, 2025
Options to purchase common stock [Member]
Schedule of Potentially Dilutive Securities of Diluted Net Loss Per Share [Line Items]
Potentially dilutive securities	5	18
Warrants for common stock [Member]
Schedule of Potentially Dilutive Securities of Diluted Net Loss Per Share [Line Items]
Potentially dilutive securities	152	165
Class A warrants for common stock [Member]
Schedule of Potentially Dilutive Securities of Diluted Net Loss Per Share [Line Items]
Potentially dilutive securities	77	77
Class B warrants for common stock [Member]
Schedule of Potentially Dilutive Securities of Diluted Net Loss Per Share [Line Items]
Potentially dilutive securities	2	2
January 2024 warrants for common stock [Member]
Schedule of Potentially Dilutive Securities of Diluted Net Loss Per Share [Line Items]
Potentially dilutive securities	1,682	1,682
January 2024 placement agent warrants for common stock [Member]
Schedule of Potentially Dilutive Securities of Diluted Net Loss Per Share [Line Items]
Potentially dilutive securities	117	117
Class C warrants for common stock [Member]
Schedule of Potentially Dilutive Securities of Diluted Net Loss Per Share [Line Items]
Potentially dilutive securities	71,873	71,873
Class E warrants for common stock [Member]
Schedule of Potentially Dilutive Securities of Diluted Net Loss Per Share [Line Items]
Potentially dilutive securities	271,277
Series F warrants for common stock [Member]
Schedule of Potentially Dilutive Securities of Diluted Net Loss Per Share [Line Items]
Potentially dilutive securities	1,125,000
Series F placement agent warrants for common stock [Member]
Schedule of Potentially Dilutive Securities of Diluted Net Loss Per Share [Line Items]
Potentially dilutive securities	45,000
Series G warrants for common stock [Member]
Schedule of Potentially Dilutive Securities of Diluted Net Loss Per Share [Line Items]
Potentially dilutive securities	3,655,917
Series G placement agent warrants for common stock [Member]
Schedule of Potentially Dilutive Securities of Diluted Net Loss Per Share [Line Items]
Potentially dilutive securities	255,914
Series H warrants for common stock [Member]
Schedule of Potentially Dilutive Securities of Diluted Net Loss Per Share [Line Items]
Potentially dilutive securities	3,655,917

Commitments and Contingencies (Details) - Toray License Agreement [Member]	6 Months Ended
	Jun. 30, 2026
Commitments and Contingencies [Line Items]
Royalty payments, percentage of net sales	7.50%
Royalty payments, tenure of committed payments	10 years
Percentage of reduction in royalty rate	50.00%

Warrants (Details) - $ / shares		1 Months Ended	6 Months Ended
Warrants (Details) - $ / shares	Aug. 07, 2026	Apr. 30, 2025	Jun. 30, 2026	Jun. 02, 2026	Oct. 31, 2025	Oct. 09, 2025
Series F Warrants [Member]
Warrants [Line Items]
Warrants exercisable term					5 years
Placement Agent Class F Warrant [Member]
Warrants [Line Items]
Warrants exercisable term					1 year 6 months
Class E Warrants [Member]
Warrants [Line Items]
Exercise price (in Dollars per share)		$ 13.68
Warrants exercisable term		5 years
Series G Warrants [Member]
Warrants [Line Items]
Exercise price (in Dollars per share)			$ 2.075
Series H Warrants [Member]
Warrants [Line Items]
Exercise price (in Dollars per share)			$ 2.075
June 2026 Series G Warrants [Member]
Warrants [Line Items]
Number of warrants issued			255,914
Exercise price (in Dollars per share)			$ 2.906
Pre-Funded Warrants [Member]
Warrants [Line Items]
Unexercised warrants			222,581
Pre-Funded Warrants [Member] \| Subsequent Event [Member]
Warrants [Line Items]
Number of warrants issued	3,433,336
June 2026 Private Placement [Member] \| Subsequent Event [Member]
Warrants [Line Items]
Unexercised warrants	222,581
Common Stock [Member] \| Series F Warrants [Member]
Warrants [Line Items]
Exercise price (in Dollars per share)					$ 7
Private Placement [Member] \| Class C Warrants [Member]
Warrants [Line Items]
Number of warrants issued		271,277
Exercise price (in Dollars per share)		$ 0.5
Private Placement [Member] \| Series E Warrants [Member]
Warrants [Line Items]
Shares issued of common stock		271,277
Private Placement [Member] \| Series G Warrants [Member]
Warrants [Line Items]
Number of warrants issued			3,655,917
Private Placement [Member] \| June 2026 Pre-Funded Warrants [Member]
Warrants [Line Items]
Number of warrants issued				3,655,917
Exercise price (in Dollars per share)			$ 0.0001
Private Placement [Member] \| Series H Warrants [Member]
Warrants [Line Items]
Number of warrants issued			3,655,917
Common Stock [Member] \| Two Thousand Twenty-Five Prefunded Warrants [Member]
Warrants [Line Items]
Number of warrants issued						518,750
Exercise price (in Dollars per share)					$ 0.0004
Common Stock [Member] \| Series F Warrants [Member]
Warrants [Line Items]
Number of warrants issued					1,125,000
Common Stock [Member] \| Placement Agent Class F Warrant [Member]
Warrants [Line Items]
Number of warrants issued					45,000
Exercise price (in Dollars per share)					$ 10
Common Stock [Member] \| Private Placement [Member] \| October Two Thousand Twenty Five Private Placement Member
Warrants [Line Items]
Number of warrants issued						43,750

Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2026

Significant Accounting Policies [Abstract]

Schedule of Potentially Dilutive Securities of Diluted Net Loss Per Share

Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows (in common stock equivalent shares):

	June 30,
Potentially Dilutive Securities Listing:	2026		2025
Options to purchase common stock		5		18
Warrants for common stock		152		165
Class A warrants for common stock		77		77
Class B warrants for common stock		2		2
January 2024 warrants for common stock		1,682		1,682
January 2024 placement agent warrants for common stock		117		117
Class C warrants for common stock		71,873		71,873
Class E warrants for common stock		271,277		271,277
Series F warrants for common stock		1,125,000		-
Series F placement agent warrants for common stock		45,000		-
Series G warrants for common stock		3,655,917		-
Series G placement agent warrants for common stock		255,914		-
Series H warrants for common stock		3,655,917		-

Stock Compensation (Details) - shares	6 Months Ended
Stock Compensation (Details) - shares	Jun. 30, 2026	Jun. 09, 2026
2018 Plan [Member]
Stock Compensation [Line Items]
Number of shares reserved for issuance	20
Shares available for grants	9
2021 Stock Plan [Member]
Stock Compensation [Line Items]
Number of shares reserved for issuance	61	600,000
Shares available for grants	600,025
Restricted Stock [Member]
Stock Compensation [Line Items]
Restricted stock award activity
Options granted

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (l)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 1D
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Supplemental Balance Sheet Information (Tables)

6 Months Ended

Jun. 30, 2026

Supplemental Balance Sheet Information [Abstract]

Schedule of Supplemental Balance Sheet Information

Prepaid expenses and other current assets consist of the following:

	June 30, 2026		December 31, 2025
Prepaid insurance	$	83,337	$	183,211
Prepaid and other		119,634		92,746
Total prepaid expenses and other current assets	$	202,971	$	275,957

Accrued expenses and other current liabilities consist of the following:

	June 30, 2026		December 31, 2025
Accrued personnel costs	$	91,911	$	47,117
Accrued legal fees		169,383		43,077
Accrued clinical trial expenses		822,178		274,532
Accrued board of director fees		147,500		147,500
Accrued other		138,136		156,567
Accrued Delaware franchise tax		-		136,149
Total accrued expenses and other current liabilities	$	1,369,108	$	804,942

Property and Equipment (Tables)

6 Months Ended

Jun. 30, 2026

Property and Equipment [Abstract]

Schedule of Property and Equipment

Property and equipment consisted of the following at June 30, 2026 and December 31, 2025:

	Depreciable lives	June 30, 2026			December 31, 2025
Construction-in-process		$	1,428,197		$	1,279,173
Manufacturing equipment	3-5 years		239,872			239,872
Furniture, Fixtures and equipment	3-5 years		132,671			116,782
Leasehold improvements	Shorter of useful life or life of lease		43,231			43,231
			1,843,971			1,679,058
Less: accumulated depreciation			(200,574	)		(144,617	)
Property and equipment, net		$	1,643,397		$	1,534,441

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Jun. 30, 2026
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false
Rule 10 b 51 Arrangement Modified	false
Non Rule 10 b 51 Arrangement Modified	false

Commitments and Contingencies

6 Months Ended

Jun. 30, 2026

Commitments and Contingencies [Abstract]

COMMITMENTS AND CONTINGENCIES

10. COMMITMENTS AND CONTINGENCIES

Minimum Royalties

As required under the License Agreement (see Note 3), following the first sale of cartridges, the Company will also make royalty payments to Toray equal to 7.5% of the net sales of the cartridges for a term of 10 years. A 50% reduction in the royalty rate applies upon expiry of applicable Toray patents on a product-by-product and country-by-country basis. There were no sales of or revenues from the cartridges through June 30, 2026.

Indemnification

The Company has certain agreements with service providers with which it does business that contain indemnification provisions pursuant to which the Company typically agrees to indemnify the party against certain types of third-party claims. The Company accrues for known indemnification issues when a loss is probable and can be reasonably estimated. The Company would also accrue for estimated incurred but unidentified indemnification issues based on historical activity. As the Company has not incurred any indemnification losses to date, there were no accruals for or expenses related to indemnification issues for any period presented.

Leases - Schedule of Lease Cost (Details) - USD ($)	6 Months Ended
Leases - Schedule of Lease Cost (Details) - USD ($)	Jun. 30, 2026	Jun. 30, 2025
Schedule of Lease Cost [Abstract]
Weighted average remaining lease term – operating leases (in years)	9 months 18 days	1 year 9 months 18 days
Weighted average remaining lease term – finance leases (in years)	1 year 7 months 6 days	2 years 7 months 6 days
Weighted average discount rate – operating leases	7.00%	7.00%
Weighted average discount rate – finance leases	7.00%	7.00%
Operating cash flows from operating leases	$ 25,000	$ 63,259
Operating cash flows from finance leases	$ 282	$ 424

Subsequent Events

6 Months Ended

Jun. 30, 2026

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

12. SUBSEQUENT EVENTS

Additional Exercises of Prefunded Warrants

2,484,367 shares of common stock were issued for June 2026 Pre-Funded Warrant exercises in July 2026. 222,581 June 2026 Pre-Funded Warrants remain unexercised as of the date of this filing.

Condensed Consolidated Statements of Changes in Stockholders’ Equity (Unaudited) (Parentheticals) - USD ($)	3 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Statement of Stockholders' Equity [Abstract]
Private placement, net of issuance costs	$ 942,262
Warrant inducement, net of issuance costs		$ 464,670
Warrant inducement costs		$ 2,706,645

License and Supply Agreement with Toray Industries

6 Months Ended

Jun. 30, 2026

License and Supply Agreement with Toray Industries [Abstract]

LICENSE AND SUPPLY AGREEMENT WITH TORAY INDUSTRIES

3. LICENSE AND SUPPLY AGREEMENT WITH TORAY INDUSTRIES

The Company depends on Toray’s intellectual property for the Symphony cartridges upon which the Symphony platform relies. On October 6, 2020, the Company entered into a License and Supply Agreement (the “License Agreement”) with Toray, providing the Company with an exclusive global license (excluding Japan) to use Toray’s patents and know-how related to the Symphony detection cartridges for manufacturing, marketing and sale of the products (as defined in the License Agreement). In exchange for the license, the Company committed to make two payments of $120,000 each to Toray, both of which were made in 2021. In addition, following the first sale of the cartridges after regulatory clearance, the Company is obligated to make royalty payments to Toray based on the net sales of the cartridges for the period that any underlying patents exist or ten years after the first sale. Following the first sale after obtaining regulatory clearance, the Company will make minimum annual royalty payments of $60,000 for the first year and $100,000 for each year thereafter, which shall be creditable against any royalties owed to Toray in such calendar year.

On October 23, 2023, the Company and Toray entered into an Amended and Restated License Agreement (the “New Toray License Agreement”) and a Master Supply Agreement (the “New Toray Supply Agreement”). Under the New Toray License Agreement, the Company continues to license from Toray intellectual property rights needed to manufacture single-use test cartridges, and the Company has received the right to sublicense certain Toray intellectual property to Sanyoseiko and Argonaut in connection with the ongoing agreement with the Company to manufacture the Company’s Symphony analyzers and cartridges (including in connection with the Company’s clinical trials). In addition, the New Toray License Agreement provided for the transfer of certain technology related to the cartridges to Sanyoseiko and Argonaut. The royalty payment percentage payable by the Company to Toray was reduced under the New Toray License Agreement from 15% to 7.5% (or less in certain circumstances) of net sales of certain cartridges for a term of 10 years. A 50% reduction in the royalty rate applies upon expiry of applicable Toray patents on a product-by-product and country-by-country basis. The New Toray License Agreement contemplates that applicable royalty payment obligations from the Company to Toray for other products will be determined separately by the parties in the future.

On July 23, 2025, the Company entered into an amendment (the “Amendment”) to the New Toray License Agreement and the New Toray Supply Agreement with Toray. The Amendment provided that the deadline under the New Toray License Agreement for the Company to establish an alternative manufacturing site for the Company’s Symphony cartridges would be extended from October 23, 2025 to October 23, 2026, and the Company has agreed to use its best efforts to establish the site by such date. The Amendment confirms that Toray has provided to the Company all applicable know-how required under the New Toray License Agreement and is not under any further obligation to provide know-how or technical assistance to the Company. Pursuant to the Amendment, the Company paid $71,212 to Toray for a final supply of certain chip components prior to the expiration of the New Toray Supply Agreement, which occurred on October 23, 2025. There were no sales of or revenues from the cartridges during the three and six-month periods ended June 30, 2026 and 2025.

The Company has completed cartridge manufacturing process redevelopment through Sanyoseiko, a third-party contractor who is managing such manufacturing process. The Company is proceeding with verification and validation testing and commercial manufacturing. At June 30, 2026 and 2025, there were no amounts accrued related to the New Toray License Agreement or the License Agreement.

Warrants (Tables)

6 Months Ended

Jun. 30, 2026

Warrants [Abstract]

Schedule of Information with Regard to Warrants Outstanding

The following table summarizes information with regard to warrants outstanding at June 30, 2026:

	Shares		Exercisable for	Weighted Average Exercise Price		Weighted Average Remaining Life (in Years)
June 2026 Pre-funded warrants		2,706,948	Common Stock	$	0.0001		-
Series G warrants		3,655,917	Common Stock	$	2.075		5.0
June 2026 Placement Agent warrants		255,914	Common Stock	$	2.906		5.0
Series H warrants		3,655,917	Common Stock	$	2.075		2.0
Series F warrants		1,125,000	Common Stock	$	7.00		4.8
Series F Placement Agent warrants		45,000	Common Stock	$	10.00		4.8
Class E warrants		271,277	Common Stock	$	13.68		3.8
Class C warrants		71,873	Common Stock	$	65.20		3.0
January 2024 warrants		1,682	Common Stock	$	2,080.00		2.5
January 2024 Placement Agent warrants		117	Common Stock	$	2,600.00		2.5
August 2023 Common Stock warrants		134	Common Stock	$	11,584.00		2.2
August 2023 Placement Agent warrants		8	Common Stock	$	14,736.00		2.2
Class A warrants		77	Common Stock	$	224,000.00		0.3
Class B warrants		2	Common Stock	$	320,000.00		0.3
Other Pre-2024 Common Stock Warrants		10	Common Stock	$	148,000.00		0.2

Supplemental Balance Sheet Information

6 Months Ended

Jun. 30, 2026

Supplemental Balance Sheet Information [Abstract]

SUPPLEMENTAL BALANCE SHEET INFORMATION

11. SUPPLEMENTAL BALANCE SHEET INFORMATION

Prepaid expenses and other current assets consist of the following:

	June 30, 2026		December 31, 2025
Prepaid insurance	$	83,337	$	183,211
Prepaid and other		119,634		92,746
Total prepaid expenses and other current assets	$	202,971	$	275,957

Accrued expenses and other current liabilities consist of the following:

	June 30, 2026		December 31, 2025
Accrued personnel costs	$	91,911	$	47,117
Accrued legal fees		169,383		43,077
Accrued clinical trial expenses		822,178		274,532
Accrued board of director fees		147,500		147,500
Accrued other		138,136		156,567
Accrued Delaware franchise tax		-		136,149
Total accrued expenses and other current liabilities	$	1,369,108	$	804,942

Leases

6 Months Ended

Jun. 30, 2026

Leases [Abstract]

LEASES

9. LEASES

The Company has lease arrangements for office space and copiers. A summary of supplemental lease information is as follows:

	Six Months Ended
	June 30, 2026			June 30, 2025
Weighted average remaining lease term – operating leases (in years)		0.8			1.8
Weighted average remaining lease term – finance leases (in years)		1.6			2.6
Weighted average discount rate – operating leases		7.0	%		7.0	%
Weighted average discount rate – finance leases		7.0	%		7.0	%
Operating cash flows from operating leases	$	25,000		$	63,259
Operating cash flows from finance leases	$	282		$	424

A summary of the Company’s lease assets and liabilities are as follows:

	June 30, 2026		December 31, 2025
Operating lease right-of-use asset	$	69,290	$	113,289
Finance lease asset – property & equipment, net		3,323		5,689
Total lease assets	$	72,613	$	118,978
Current portion of operating lease liability	$	73,444	$	100,000
Current portion of finance lease liability included in accrued expenses		4,807		4,807
Non-current portion of operating lease liabilities		-		20,211
Non-current portion of finance lease liabilities included in other non-current liabilities		2,419		4,540
Total lease liabilities	$	80,670	$	129,558

A summary of the Company’s estimated operating lease payments are as follows:

Year
2026 ⁽¹⁾	$	50,000
2027		25,000
Thereafter		-
Total future lease payments		75,000
Less: Imputed interest		1,556
Present value of lease liability	$	73,444

(1)	Excludes the six months ended June 30, 2026

Nature of Operations and Basis of Presentation

6 Months Ended

Jun. 30, 2026

Nature of Operations and Basis of Presentation [Abstract]

NATURE OF OPERATIONS AND BASIS OF PRESENTATION

1. NATURE OF OPERATIONS AND BASIS OF PRESENTATION

Business

Bluejay Diagnostics, Inc. (“Bluejay” and/or the “Company”) is a medical diagnostics company focused on improving patient outcomes in critical care settings, with a focus on sepsis. The Company is working on developing rapid, near-patient tests using whole blood on its Symphony technology platform (“Symphony”), which consists of an analyzer and single-use protein detection cartridges. The Company does not yet have regulatory clearance for Symphony, and it will need to receive regulatory authorization from the U.S. Food and Drug Administration (the “FDA”) before Symphony can be marketed as a diagnostic product in the United States. The Company has completed the development of the Symphony analyzer. During 2025, the Company transferred the intellectual property underlying the production of the Symphony cartridges from the original developer and outside supplier, Toray Industries, Inc. (“Toray”), to a contract manufacturing facility with FDA certification run by Sanyoseiko Co. Ltd. (“Sanyoseiko”). On May 27, 2026, the Company entered into an agreement and statement of work with Argonaut Manufacturing (“Argonaut”) to provide the Company with US based manufacturing to de-risk the Company’s overseas manufacturing. In July 2026, the Company announced that it has successfully completed patient enrollment of its SYMON-II clinical validation study for IL-6. The Company is now progressing toward analytical and clinical validation to support a regulatory submission. To achieve its commercial plan, the Company expects to need to raise between $10.0 million and $14.0 million of further capital by the end of the 2027 fiscal year for commercialization, which the Company hopes to do in various tranches.

The Company’s Symphony platform is a combination of Bluejay’s intellectual property (“IP”) and exclusively licensed and patented IP on the Symphony technology that the Company believes if cleared, authorized, or approved by the FDA, could provide a solution to a significant market need in the United States. The Symphony device candidate is designed to produce laboratory-quality results in approximately 20 minutes in critical care settings, including Intensive Care Units (“ICUs”) and Emergency Rooms (“ERs”), where rapid and reliable results are required.

The Company’s first product candidate, the Symphony IL-6 test, is an immunoassay for the measurement of interleukin-6 (IL-6) to be used for the monitoring of disease progression in critical care settings. The Company is currently focused on pursuing the Symphony IL-6 test in the context of sepsis. IL-6 is a clinically established inflammatory biomarker, and is considered a ‘first-responder,’ for assessment of severity of infection and inflammation across many disease indications, including sepsis. A current challenge of healthcare professionals is the excessive time and cost associated with determining a patient’s level of severity at triage and the Company believes that its Symphony IL-6 test, if ultimately successful and approved, could have the ability to consistently monitor this critical care biomarker with rapid results.

If the Company succeeds with the foregoing plan, in the future it hopes to develop additional tests for Symphony, including tests for myocardial infarction and congestive heart failure (cardiac biomarkers hsTNT and NT pro-BNP) as well as other tests using the Symphony platform.

The Company was incorporated under the laws of Delaware on March 20, 2015. Its headquarters are located in Acton, Massachusetts.

On June 4, 2021, the Company formed Bluejay Spinco, LLC, a wholly-owned subsidiary of the Company, for purposes of further development of the Company’s ALLEREYE diagnostic test. ALLEREYE is a point-of-care device offering healthcare providers a solution for diagnosing Allergic Conjunctivitis. The Company currently is not actively pursuing development of the ALLEREYE diagnostic test. On March 3, 2026, the Company completed the dissolution of its wholly owned subsidiary Bluejay Spinco, LLC.

FDA Regulatory Strategy

The sale of the Company’s products in the U.S. are subject to regulation by the FDA. Generally, the products we develop must be cleared by the FDA before they are marketed in the United States. Before and after approval, authorization, or clearance in the United States, our products are subject to extensive regulation by the FDA, as well as by other regulatory bodies. FDA regulations govern, among other things, the development, testing, manufacturing, labeling, safety, storage, recordkeeping, market clearance, authorization or approval, labeling and promotion, import and export, marketing and sales, and distribution of medical devices.

The Company’s current regulatory strategy is designed to support commercialization of Symphony in the United States if and when the Company receives marketing authorization from the FDA. In May 2023, the Company submitted a pre-submission application to the FDA presenting study designs to validate Symphony IL-6 for use with hospitalized sepsis patients. The Company participated in a pre-submission meeting with the FDA in August 2023, and at the meeting the FDA provided feedback on the study design, determined that the submission of a 510(k) is the appropriate premarket submission pathway, and requested that certain data be provided in the 510(k). Based on this feedback, the Company is determined to proceed on this basis, which considers the FDA’s feedback.

In the second quarter of 2024, the Company completed a multicenter SYmphony IL-6 MONitoring Sepsis (“SYMON”) pilot clinical study investigating the role of interleukin-6 (IL-6) in patients diagnosed with sepsis and septic shock. This prospective study assessed the performance of IL-6 upon initial presentation to the intensive care unit (ICU). A primary endpoint of the SYMON-I pilot clinical study (registered clinical trial number NCT06181604) suggested that IL-6 levels within 24 hours of sepsis or septic shock diagnosis and admission to the ICU may predict patient mortality out to 28 days. Furthermore, a secondary endpoint of the SYMON-I study suggested that IL-6 levels within 24 hours of sepsis or septic shock diagnosis and admission to the ICU is a predictor of patient mortality during their hospitalization. Other secondary endpoints suggested that lactate and Sequential Organ Failure Assessment (SOFA), standard clinical tests used for sepsis and septic shock patients, were not predictors of patient mortality out to 28 days. We believe that the findings underscore the potential importance of IL-6 as a predictor and provide new insights into the potential pathways for improving sepsis outcomes.

Using the data analysis from the SYMON-I pilot clinical study, the Company initiated the SYMON-II pivotal clinical study in the third quarter of 2024. The SYMON II clinical study has three components: (1) collection, freezing, and biobanking of patient samples, (2) measuring IL-6 concentrations in the biobanked samples near the end of patient enrollment or after the patient enrollment has completed, and (3) analysis of the IL-6 data with the patient outcomes to see if the established IL-6 cutoff value has been validated for 28-day all-cause mortality. Patient enrollment started during the fourth quarter of 2024. The Company has now successfully completed enrollment of the targeted 750 hospital patients, and it has collected, frozen and biobanked blood samples from the enrolled patients, while also obtaining all related patient data regarding their disease progression and outcomes. The Company has initiated preliminary testing of the samples, and preliminary patient data analysis. The final analytical testing will be performed upon verification and validation of the cartridges in accordance with FDA 820 QSR guidelines. The Company’s goal is to produce and verify these cartridges during 2026.

If the Company is able to complete the SYMON-II clinical study and the results are positive, the Company intends to use the data generated from SYMON-II to support a 510(k) application to the FDA. This application is currently expected to be based on the following intended use: “Symphony IL-6 is intended for use to determine the IL-6 concentration as an aid in assessing the cumulative 28-day risk of all-cause mortality in conjunction with other laboratory findings and clinical assessments for patients diagnosed with sepsis or septic shock in the ICU.” The Company also plans to present the SYMON-I and SYMON-II results at future national scientific meetings and publish them in peer-reviewed journals, subject to future completion of the SYMON-II study and the results being positive. Subject to achieving needed funding and successfully achieving commercial grade manufacturing with its cartridges, the Company’s plan is to begin testing of samples it is collecting as part of the SYMON-II clinical trial by the end of 2026, with a goal of being in position to submit a 510(k) regulatory application to the FDA during the first half of 2027, and an objective of achieving FDA clearance thereafter.

The Company’s ability to complete the activities needed for an FDA submission will be contingent upon meeting analytical validation and clinical validation.

Product Manufacturing

The Company plans to manufacture its analyzers through Sanyoseiko and cartridges through both Sanyoseiko and Argonaut, as a contract manufacturing organization (“CMO”), and the Company has entered into commercial agreements with Sanyoseiko and Argonaut governing these matters. Pursuant to statements of work that the Company has begun providing to Sanyoseiko under these agreements, Sanyoseiko will provide end-to-end support for the Symphony platform, including supporting the manufacturing process for analyzers and cartridges (with hardware, software, and design updates), managing raw material sourcing and vendor compliance, and serving as the Company’s contract manufacturing organization for analyzers, cartridges, and related components. Argonaut will provide fill-and-seal of the reagent reservoir, final assembly, labelling, packaging, storage, release criteria and distribution of the cartridges in the US and globally.

Risks and Uncertainties

As noted above, the Company will be reliant upon its CMOs, Sanyoseiko and Argonaut, to provide analyzers and cartridges in sufficient quantity and quality to complete the validations for its FDA application. The Company’s FDA application submission could be delayed if the Company encounters any material supply interruptions. In addition, there can be no assurance that the Company will be able to obtain necessary regulatory authorization for the marketing of the Symphony in the United States or elsewhere. There also can be no assurance that the Company will successfully complete any clinical evaluations necessary to receive regulatory clearances, or that the clinical study will demonstrate sufficient effectiveness of the Symphony IL-6 test. The failure to adequately demonstrate the clinical performance of the Symphony IL-6 test could delay or prevent regulatory clearance, which could prevent or result in delays to market launch and could materially harm the Company’s business.

In addition to the FDA regulatory strategy risks and uncertainties, the Company is subject to a number of risks similar to other companies in its industry, including rapid technological change, competition from larger biotechnology companies and dependence on key personnel. Additional risk and uncertainties regarding the Company are described in “Part I – Item 1A. Risk Factors” of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and in in “Part II – Item 1A Risk Factors” of this Quarterly Report on Form 10-Q.

Reverse Stock Splits and Increase to Authorized Capital

On January 29, 2026, the Company effected a reverse stock split of its shares of common stock at a ratio of 1-for-4 (the “January 2026 Reverse Stock Split”). All of the Company’s historical share and per share information related to issued and outstanding common stock and outstanding options and warrants exercisable for common stock in these financial statements have been adjusted, on a retroactive basis, to reflect the January 2026 Reverse Stock Split and other reverse stock splits consummated by the Company in prior years.

At the Company’s annual meeting of stockholders on June 9, 2026, the Company’s stockholders provided the Company’s board of directors with authority to implement an additional reverse stock split at a ratio of up to 1-for-20 (the “Additional Reverse Stock Split”). The Additional Reverse Stock Split may not be implemented if it would reduce the number of publicly held shares of the Company’s common stock to less than 500,000. The Board’s authority to implement the Additional Reverse Stock expires on June 9, 2027. The Board has no present intention of implementing the Additional Reverse Stock Split during the 12-month period for which approval has been obtained. The Board sought approval of the Additional Reverse Stock Split to give the Company flexibility in the future in the event that the Company’s common stock declines in value and no longer meets Nasdaq’s minimum $1.00 minimum bid price requirement.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in conformity with generally accepted accounting principles in the United States (“US GAAP”) consistent with those applied in, and should be read in conjunction with, the Company’s audited financial statements and related footnotes for the year ended December 31, 2025 included in the Company’s Annual Report on Form 10-K. The unaudited condensed consolidated financial statements reflect all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position as of June 30, 2026, its results of operations and cash flows for the three and six months ended June 30, 2026 and 2025, in accordance with US GAAP. The unaudited condensed consolidated financial statements do not include all of the information and footnotes required by US GAAP for complete financial statements, as allowed by the relevant U.S. Securities and Exchange Commission (“SEC”) rules and regulations; however, the Company believes that its disclosures are adequate to ensure that the information presented is not misleading. The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation.

The results for the three and six months ended June 30, 2026 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2026, or any other interim period within this fiscal year.

Going Concern

The accompanying unaudited condensed consolidated financial statements for the three and six months ended June 30, 2026 and 2025 were prepared under the assumption that the Company will continue as a going concern, which contemplates that the Company will be able to realize assets and discharge liabilities in the normal course of business.

The Company had cash and cash equivalents of $9,598,916 and current liabilities of $2,116,641 as of June 30, 2026. The Company has incurred net losses and negative cash flows from operations since its inception and has an accumulated deficit of $45,760,521 as of June 30, 2026. The Company expects that its net cash used in operating activities will continue to be negative over at least the next several years as it attempts to produce product capable of meeting analytical validation and clinical validation and conducts clinical trial work and, if such production and trials are successful, prepares an FDA submission. These financial results and financial position, and the Company’s expected forward-looking outlook of significant negative cash flow in the future, raise substantial doubt with respect to its ability to continue as a going concern. The Company expects that it will be in position to submit a 510(k) regulatory application to the FDA for Symphony during the first half of 2027, assuming that it is able to generate sufficient clinical trial results to support such a submission. If the Company fails to obtain sufficient future financing, its clinical trials and targeted FDA submission timeline could be delayed, and it could be forced to abandon such activities entirely and cease operations, with the possible loss of such properties or assets. If the Company is unable to obtain additional financing as it continues to generate negative cash flow, its board of directors could determine to cause the Company to undertake a process of liquidation under Chapter 7 of applicable U.S. bankruptcy laws, or otherwise seek other protection under such laws. In such event, holders of shares of the Company’s common stock could recoup little, if any, value in such process. The Company currently estimates cash resources will be sufficient to fund its operations through the second quarter of 2027.

These accompanying financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.

Warrants

6 Months Ended

Jun. 30, 2026

Warrants [Abstract]

WARRANTS

5. WARRANTS

The following table summarizes information with regard to warrants outstanding at June 30, 2026:

	Shares		Exercisable for	Weighted Average Exercise Price		Weighted Average Remaining Life (in Years)
June 2026 Pre-funded warrants		2,706,948	Common Stock	$	0.0001		-
Series G warrants		3,655,917	Common Stock	$	2.075		5.0
June 2026 Placement Agent warrants		255,914	Common Stock	$	2.906		5.0
Series H warrants		3,655,917	Common Stock	$	2.075		2.0
Series F warrants		1,125,000	Common Stock	$	7.00		4.8
Series F Placement Agent warrants		45,000	Common Stock	$	10.00		4.8
Class E warrants		271,277	Common Stock	$	13.68		3.8
Class C warrants		71,873	Common Stock	$	65.20		3.0
January 2024 warrants		1,682	Common Stock	$	2,080.00		2.5
January 2024 Placement Agent warrants		117	Common Stock	$	2,600.00		2.5
August 2023 Common Stock warrants		134	Common Stock	$	11,584.00		2.2
August 2023 Placement Agent warrants		8	Common Stock	$	14,736.00		2.2
Class A warrants		77	Common Stock	$	224,000.00		0.3
Class B warrants		2	Common Stock	$	320,000.00		0.3
Other Pre-2024 Common Stock Warrants		10	Common Stock	$	148,000.00		0.2

June 2026 Private Placement

June 2026 Series G Warrants, June 2026 Placement Agent Warrants and Series H Warrants

The Series G Warrants and Series H Warrants are immediately exercisable for shares of common stock at an exercise price of $2.075 per share. The Series G Warrants expire on June 26, 2031 and the Series H Warrants expire on June 26, 2028. Under the terms of the Company’s engagement letter with Wainwright, the Company issued Wainwright (or its designees) warrants to purchase up to 255,914 shares of common stock on the same terms as the Series G Warrants, except that the exercise price is $2.906 per share.

October 2025 Private Placement

October 2025 Series F Warrants

Pursuant to the October 2025 private placement, the Company issued 1,125,000 Series F warrants for common stock with an exercise price of $7.00 per share and 45,000 Placement Agent Series F warrants for common stock with an exercise price of $10.00 per share. The Series F warrants and Placement Agent Series F warrants became exercisable immediately upon issuance and for a period of five and one half years following the date of issuance.

April 2025 Class E Warrants

Pursuant to the April 2025 private placement, certain existing holders of the Company’s Class C Warrants agreed to purchase an aggregate of 271,277 shares of the Company’s common stock. As a part of the April 2025 private placement, the Company sold 271,277 Class E Warrants to the Class C Warrant exercising holders for $0.50 per warrant. The Class E warrants have an exercise price of $13.68 per share, became exercisable immediately upon issuance and for a period of five years following the date of issuance.

Fundamental Transaction

The warrants described above include certain rights upon a “fundamental transaction” (as defined in such warrants), including the right of the holders thereof to receive from the Company or a successor entity cash or the same type or form of consideration (and in the same proportion) that is being offered and paid to the holders of common stock in such fundamental transaction in the amount of the Black Scholes value (as defined in such warrants) of the unexercised portion of the applicable warrants on the date of the consummation of such fundamental transaction.

Warrant Accounting

Each of the Company’s warrants to acquire shares of common stock were accounted for as equity classified financial instruments as they meet the requirements for equity classification under ASC 815, Derivatives and Hedging.

Leases (Tables)

6 Months Ended

Jun. 30, 2026

Leases [Abstract]

Schedule of Lease Cost

A summary of supplemental lease information is as follows:

	Six Months Ended
	June 30, 2026			June 30, 2025
Weighted average remaining lease term – operating leases (in years)		0.8			1.8
Weighted average remaining lease term – finance leases (in years)		1.6			2.6
Weighted average discount rate – operating leases		7.0	%		7.0	%
Weighted average discount rate – finance leases		7.0	%		7.0	%
Operating cash flows from operating leases	$	25,000		$	63,259
Operating cash flows from finance leases	$	282		$	424

Schedule of Lease Assets and Liabilities

A summary of the Company’s lease assets and liabilities are as follows:

	June 30, 2026		December 31, 2025
Operating lease right-of-use asset	$	69,290	$	113,289
Finance lease asset – property & equipment, net		3,323		5,689
Total lease assets	$	72,613	$	118,978
Current portion of operating lease liability	$	73,444	$	100,000
Current portion of finance lease liability included in accrued expenses		4,807		4,807
Non-current portion of operating lease liabilities		-		20,211
Non-current portion of finance lease liabilities included in other non-current liabilities		2,419		4,540
Total lease liabilities	$	80,670	$	129,558

Schedule of Estimated Operating Lease Payments

A summary of the Company’s estimated operating lease payments are as follows:

Year
2026 ⁽¹⁾	$	50,000
2027		25,000
Thereafter		-
Total future lease payments		75,000
Less: Imputed interest		1,556
Present value of lease liability	$	73,444

(1)	Excludes the six months ended June 30, 2026

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	Jun. 30, 2026	Dec. 31, 2025
Schedule of Property and Equipment [Line Items]
Property and equipment, gross	$ 1,843,971	$ 1,679,058
Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]	Leasehold Improvements [Member]
Less: accumulated depreciation	$ 200,574	144,617
Property and equipment, net	1,643,397	1,534,441
Construction in process [Member]
Schedule of Property and Equipment [Line Items]
Property and equipment, gross	1,428,197	1,279,173
Manufacturing equipment [Member]
Schedule of Property and Equipment [Line Items]
Property and equipment, gross	$ 239,872	239,872
Manufacturing equipment [Member] \| Minimum [Member]
Schedule of Property and Equipment [Line Items]
Property and equipment, Depreciable lives	3 years
Manufacturing equipment [Member] \| Maximum [Member]
Schedule of Property and Equipment [Line Items]
Property and equipment, Depreciable lives	5 years
Furniture, Fixtures, and equipment [Member]
Schedule of Property and Equipment [Line Items]
Property and equipment, gross	$ 132,671	116,782
Furniture, Fixtures, and equipment [Member] \| Minimum [Member]
Schedule of Property and Equipment [Line Items]
Property and equipment, Depreciable lives	3 years
Furniture, Fixtures, and equipment [Member] \| Maximum [Member]
Schedule of Property and Equipment [Line Items]
Property and equipment, Depreciable lives	5 years
Leasehold Improvements [Member]
Schedule of Property and Equipment [Line Items]
Property and equipment, gross	$ 43,231	$ 43,231

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (4,243,254)	$ (3,821,039)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	55,956	36,143
Stock-based compensation expense		(251)
Amortization of right-of-use asset	43,999	54,105
Write-off and impairment of property and equipment	2,880	495
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	72,986	291,460
Other non-current assets	1,644	13,093
Accounts payable	459,834	(36,305)
Accrued expenses and other current liabilities	517,399	223,387
Net cash used in operating activities	(3,088,556)	(3,238,912)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(161,762)
Proceeds from sale of property and equipment	3,675
Net cash used in investing activities	(158,087)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock and pre-funded warrants, gross	8,624,835	3,846,692
Issuance costs related to issuance of common stock	(942,262)	(464,670)
Proceeds from exercise of prefunded warrants	232
Payment of finance lease	(2,121)	(1,979)
Net cash provided by financing activities	7,680,684	3,380,043
Increase in cash and cash equivalents	4,434,041	141,131
Cash and cash equivalents, beginning of period	5,164,875	4,301,945
Cash and cash equivalents, end of period	$ 9,598,916	$ 4,443,076

Financings (Details) - USD ($)								6 Months Ended
Financings (Details) - USD ($)	Aug. 07, 2026	Mar. 17, 2026	Mar. 14, 2026	Oct. 10, 2025	Oct. 09, 2025	Apr. 07, 2025	Aug. 21, 2024	Jun. 30, 2026	Jun. 30, 2025	Jun. 26, 2026	Jun. 02, 2026	Dec. 31, 2025	Nov. 26, 2025	Apr. 30, 2025	Apr. 08, 2025	Jun. 28, 2024
Financings [Line Items]
Aggregate gross proceeds								$ 8,624,835	$ 3,846,692
Gross proceeds				$ 4,500,000
Total offering costs						$ 464,670
Advisory fee						384,670
Common stock for resale								1,983,684				604,534
Beneficial ownership limitation								9.99%
Calendar days								61 days
Exercise price reduced							$ 65.2
Inducement transaction						$ 1,590,930
Percentage of financial advisory fee						10.00%
Rodman and Renshaw LLC [Member]
Financings [Line Items]
Purchase of shares				45,000
Exercise price				$ 10
Expiration period				5 years 6 months
Total offering costs				$ 787,755
Advisory fee				$ 360,000
Percentage of financial advisory fee				8.00%
October 2025 Prefunded Warrants [Member]
Financings [Line Items]
Exercise price					$ 0.0004
Series F Warrants [Member]
Financings [Line Items]
Purchase of shares					1,125,000
Exercise price					$ 7
Prefunded Warrant [Member] \| Subsequent Event [Member]
Financings [Line Items]
Exercise price shares	3,433,336
Unexercised Warrants	222,581
Class C Warrants [Member]
Financings [Line Items]
Price per share															$ 0.0004
Class E Warrants [Member]
Financings [Line Items]
Exercise price														$ 13.68
Expiration period														5 years
Additional per share						$ 0.5
Sale amount						$ 3,846,692
Series C Warrants [Member]
Financings [Line Items]
Inducement transaction						479,299
Series E Warrants [Member]
Financings [Line Items]
Fair value						1,730,652
Warrant [Member]
Financings [Line Items]
Inducement transaction						135,638
Series G Warrants [Member]
Financings [Line Items]
Exercise price								$ 2.075
Series H Warrants [Member]
Financings [Line Items]
Exercise price								2.075
June 2026 Placement Agent Warrants [Member]
Financings [Line Items]
Exercise price								$ 2.906
Expiration period								5 years
Series C Warrants and issuance of Series E Warrants [Member]
Financings [Line Items]
Equity issuance cost						$ 2,706,645
Maximum [Member]
Financings [Line Items]
Beneficially own in excess percentage								9.99%
Minimum [Member]
Financings [Line Items]
Beneficially own in excess percentage								4.99%
March 2026 Private Placement [Member]
Financings [Line Items]
Aggregate of shares			62,500					12,500
Aggregate gross proceeds		$ 125,000
Private Placement [Member]
Financings [Line Items]
Common stock for resale													1,732,500
Private Placement [Member] \| Class C Warrants [Member]
Financings [Line Items]
Purchase of shares														271,277
Exercise price														$ 0.5
Private Placement [Member] \| June 2026 Pre-Funded Warrants [Member]
Financings [Line Items]
Purchase of shares											3,655,917
Exercise price								$ 0.0001
Private Placement [Member] \| Series G Warrants [Member]
Financings [Line Items]
Purchase of shares								3,655,917
Private Placement [Member] \| Series H Warrants [Member]
Financings [Line Items]
Purchase of shares								3,655,917
April 2025 Private Placement [Member]
Financings [Line Items]
Purchase of shares						271,277
Exercise price																$ 392
Exercise price reduced						$ 13.68
April 2025 Private Placement [Member] \| Class C Warrants [Member]
Financings [Line Items]
Purchase of shares															170,551
Exercise price						0.0004
Exercise price shares															100,726
April 2025 Private Placement [Member] \| Class E Warrants [Member]
Financings [Line Items]
Exercise price						$ 13.68
Expire date						Apr. 08, 2030
June 2026 Private Placement [Member]
Financings [Line Items]
Exercise price											$ 0.0001
Gross proceeds								$ 8,500,000
Total offering costs								942,262
Advisory fee								$ 595,000
Beneficial ownership limitation								9.99%
Calendar days								61 days
Percentage of financial advisory fee								7.00%
June 2026 Private Placement [Member] \| Series G Warrants [Member]
Financings [Line Items]
Purchase of shares								255,914
Expire date											Jun. 26, 2031
June 2026 Private Placement [Member] \| Series H Warrants [Member]
Financings [Line Items]
Expire date											Jun. 26, 2028
June 2026 Private Placement [Member] \| Series G Warrants and Series H Warrants [Member]
Financings [Line Items]
Price per unit											$ 2.3249
Exercise price											$ 2.075
June 2026 Private Placement [Member] \| June 2026 Placement Agent Warrants [Member]
Financings [Line Items]
Exercise price								$ 2.9063
June 2026 Private Placement [Member] \| Maximum [Member]
Financings [Line Items]
Beneficially own in excess percentage								9.99%
June 2026 Private Placement [Member] \| Minimum [Member]
Financings [Line Items]
Beneficially own in excess percentage								4.99%
Common Stock [Member] \| October 2025 Prefunded Warrants [Member]
Financings [Line Items]
Purchase of shares					518,750
Common Stock [Member] \| Prefunded Warrant [Member]
Financings [Line Items]
Price per unit					$ 0.0004
Common Stock [Member] \| Maximum [Member] \| Series F Warrants [Member]
Financings [Line Items]
Expiration period					5 years
Common Stock [Member] \| Minimum [Member] \| Series F Warrants [Member]
Financings [Line Items]
Expiration period					1 year 6 months
Common Stock [Member] \| March 2026 Private Placement [Member]
Financings [Line Items]
Price per unit			$ 2
Common Stock [Member] \| Private Placement [Member]
Financings [Line Items]
Price per unit					$ 8
Common Stock [Member] \| June 2026 Private Placement [Member]
Financings [Line Items]
Common stock for resale										11,223,665
Common Stock [Member] \| June 2026 Private Placement [Member] \| June 2026 Pre-Funded Warrants [Member]
Financings [Line Items]
Purchase of shares											3,655,917
Common Stock [Member] \| June 2026 Private Placement [Member] \| Series G Warrants [Member]
Financings [Line Items]
Purchase of shares											3,655,917
Common Stock [Member] \| June 2026 Private Placement [Member] \| Series H Warrants [Member]
Financings [Line Items]
Purchase of shares											3,655,917
Common Stock [Member] \| October 2025 Private Placement [Member]
Financings [Line Items]
Aggregate of shares					43,750

Stock Compensation - Schedule of Stock Option Activity (Details) - Stock Option [Member] - USD ($)		6 Months Ended
	Dec. 31, 2025	Jun. 30, 2026
Schedule of Stock Option Activity [Line Items]
Number of Stock Options, Outstanding Balance	5	5
Weighted Average Exercise Price Per Share, Outstanding Balance	$ 20,376	$ 20,376
Weighted Average Remaining Contractual Life in Years, Outstanding Balance	3 years	2 years 6 months
Aggregate Intrinsic Value, Outstanding Balance
Number of Stock Options, Exercisable		5
Weighted Average Exercise Price Per Share, Exercisable		$ 20,376
Weighted Average Remaining Contractual Life in Years, Exercisable		2 years 6 months
Aggregate Intrinsic Value, Exercisable
Number of Stock Options, Granted
Weighted Average Exercise Price Per Share, Granted
Aggregate Intrinsic Value, Granted
Number of Stock Options, Exercised
Weighted Average Exercise Price Per Share, Exercised
Aggregate Intrinsic Value, Exercised
Number of Stock Options, Cancelled and forfeited
Weighted Average Exercise Price Per Share, Cancelled and forfeited
Aggregate Intrinsic Value, Cancelled and forfeited

Leases - Schedule of Lease Assets and Liabilities (Details) - USD ($)	Jun. 30, 2026	Dec. 31, 2025
Schedule of Lease Assets and Liabilities [Abstract]
Operating lease right-of-use asset	$ 69,290	$ 113,289
Finance lease asset – property & equipment, net	3,323	5,689
Total lease assets	72,613	118,978
Current portion of operating lease liability	$ 73,444	$ 100,000
Current portion of finance lease liability included in accrued expenses	Accrued expenses and other current liabilities	Accrued expenses and other current liabilities
Current portion of finance lease liability included in accrued expenses	$ 4,807	$ 4,807
Non-current portion of operating lease liabilities		$ 20,211
Finance lease liability, noncurrent	Noncurrent finance lease liabilities	Noncurrent finance lease liabilities
Non-current portion of finance lease liabilities included in other non-current liabilities	$ 2,419	$ 4,540
Total lease liabilities	$ 80,670	$ 129,558

Related Party Transactions (Tables)

6 Months Ended

Jun. 30, 2026

Schedule of Due from Related Parties

The table below summarizes the amounts earned and due from NanoHybrids as of and for the three and six-month periods ended June 30, 2026 and 2025:

	Three Months Ended June 30,				Six Months Ended June 30,
	2026		2025		2026		2025
Income from NanoHybrids included in other income	$	-	$	-	$	-	$	6,873
Cash receipts from NanoHybrids	$	-	$	6,873	$	-	$	21,437

Significant Accounting Policies (Details)	6 Months Ended
Significant Accounting Policies (Details)	Jun. 30, 2026
Significant Accounting Policies [Line Items]
Operating segment	1
Reportable segment	1
Description of CODM	the Chief Executive Officer, who serves as the Chief Operating Decision Maker, evaluates performance of the operating segment and allocates resources based on amounts as reported on the consolidated statements of operations and cash flows.
Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]	Chief Executive Officer

Stock Compensation - Schedule of Stock-Based Compensation Expense (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Schedule of Stock-Based Compensation Expense [Line Items]
Stock-based compensation expense		$ (1,563)		$ (251)
Research and development [Member]
Schedule of Stock-Based Compensation Expense [Line Items]
Stock-based compensation expense		(1,563)		(450)
General and administrative [Member]
Schedule of Stock-Based Compensation Expense [Line Items]
Stock-based compensation expense				$ 199

Accounting Policies, by Policy (Policies)

6 Months Ended

Jun. 30, 2026

Significant Accounting Policies [Abstract]

Use of Estimates

Warrants

Segment Reporting

Net Loss per Share

Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows (in common stock equivalent shares):

	June 30,
Potentially Dilutive Securities Listing:	2026		2025
Options to purchase common stock		5		18
Warrants for common stock		152		165
Class A warrants for common stock		77		77
Class B warrants for common stock		2		2
January 2024 warrants for common stock		1,682		1,682
January 2024 placement agent warrants for common stock		117		117
Class C warrants for common stock		71,873		71,873
Class E warrants for common stock		271,277		271,277
Series F warrants for common stock		1,125,000		-
Series F placement agent warrants for common stock		45,000		-
Series G warrants for common stock		3,655,917		-
Series G placement agent warrants for common stock		255,914		-
Series H warrants for common stock		3,655,917		-

Recently Issued Accounting Standards

Recently Issued Accounting Standards

Expense Disaggregation Disclosures

- Definition

Disclosure of accounting policy for its derivative instruments and hedging activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482913/230-10-50-9

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-8

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-8

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479693/815-10-S50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-8C

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-8

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-7

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4F
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4F

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/815/tableOfContent

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(n))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

+ Details

- Definition

Disclosure of accounting policy for segment reporting.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 29
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-29

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 29
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-29

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 29
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-29

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (bb)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 29
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-29

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 36
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-36

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 29
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-29

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 29
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-29

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 29
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-29

+ Details

- Definition

Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-12

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-9

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482836/275-10-55-6

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-6

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-4

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-SubTopic 10
-Topic 275
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-SubTopic 10
-Topic 275
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-1

+ Details

Related Party Transactions

6 Months Ended

Jun. 30, 2026

RELATED PARTY TRANSACTIONS

7. RELATED PARTY TRANSACTIONS

March 2026 Private Placement

The purchasers were Neil Dey, President and Chief Executive Officer of the Company and a director, Donald Chase, Chairman of the Board, and Svetlana Dey, Douglas Wurth and Fred Zeidman, each of whom are directors. Each of the purchasers acquired 12,500 shares of common stock for their own individual account.

NanoHybrids, LLC

In December 2021, the Company entered into an agreement with NanoHybrids, Inc. (“NanoHybrids”), an entity in which the Company’s former Chief Technology Officer, Jason Cook, served as Chief Executive Officer of prior to becoming employed by the Company, to enable NanoHybrids to utilize the Company’s research and development staff and laboratory facility (the “Sharing and Services Agreement”). Any hours worked by Company employees for NanoHybrids were billed to NanoHybrids at a bill rate of the respective employee’s fully burdened personnel cost plus 10%. Dr. Cook was the majority shareholder of NanoHybrids during the time of this arrangement. The table below summarizes the amounts earned and due from NanoHybrids as of and for the three and six-month periods ended June 30, 2026 and 2025:

	Three Months Ended June 30,				Six Months Ended June 30,
	2026		2025		2026		2025
Income from NanoHybrids included in other income	$	-	$	-	$	-	$	6,873
Cash receipts from NanoHybrids	$	-	$	6,873	$	-	$	21,437

There were no balances due as of June 30, 2026 and December 31, 2025.

On May 8, 2025, the Company entered into a settlement and release agreement with Nanohybrids that terminated the respective parties’ obligations under the Sharing and Services Agreement, and memorialized that prior discussions between the parties regarding a potential sale of Nanohybrids to the Company (the “Strategic Transaction Discussions”) were terminated. Under the terms of such agreement, the Company agreed to make payment of $50,000 to Nanohybrids and reimburse Nanohybrids for up to $30,000 in reasonable and documented attorneys’ fees that Nanohybrids had previously incurred in connection with the Strategic Transaction Discussions. The Company and Nanohybrids (including Dr. Cook for this limited purpose) each also provided the other with releases related to the Sharing and Services Agreement and the Strategic Transaction Discussions.

Each of the foregoing agreements was approved in advance by the Audit Committee of the Company’s Board of Directors.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

+ Details

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Operating expenses:
Research and development	$ 1,437,806	$ 889,896	$ 2,249,643	$ 1,674,696
General and administrative	911,318	1,095,465	2,038,312	2,199,582
Total operating expenses	2,349,124	1,985,361	4,287,955	3,874,278
Operating loss	(2,349,124)	(1,985,361)	(4,287,955)	(3,874,278)
Other income:
Interest income	24,829	29,254	43,688	47,055
Other income (expense), net	282	(497)	1,013	6,184
Total other income, net	25,111	28,757	44,701	53,239
Net loss	$ (2,324,013)	$ (1,956,604)	$ (4,243,254)	$ (3,821,039)
Net loss per share – Basic	$ (1.12)	$ (5.64)	$ (2.77)	$ (15.75)
Net loss per share – Diluted	$ (1.12)	$ (5.64)	$ (2.77)	$ (15.75)
Weighted average common shares outstanding – Basic	2,079,263	346,780	1,531,999	242,641
Weighted average common shares outstanding – Diluted	2,079,263	346,780	1,531,999	242,641

Property and Equipment (Details) - USD ($)	6 Months Ended		12 Months Ended
Property and Equipment (Details) - USD ($)	Jun. 30, 2026	Jun. 30, 2025	Dec. 31, 2025
Property and Equipment [Line Items]
Fixed assets of net book value			$ 62,376
Equipment expense	$ 9,549
Impairment charge	26,706
Assets held for sale	3,675
Wrote-off assets held for sale	2,880	$ 495
Furniture, fixtures and equipment [Member]
Property and Equipment [Line Items]
Assets held for sale	3,150
Construction in process [Member]
Property and Equipment [Line Items]
Property and equipment	1,105,440
Manufacturing equipment [Member]
Property and Equipment [Line Items]
Property and equipment	$ 179,904